Summary & Overview
HCPCS J1749: Iloprost Injection, 0.1 mcg
HCPCS Level II code J1749 designates a 0.1 mcg unit of iloprost administered by injection. Iloprost is a prostacyclin analogue used in specialized vascular and pulmonary therapies; accurate coding of drug units is essential for consistent billing, clinical documentation, and national aggregation of utilization and cost information. This code matters nationally because biologic and infusion therapies increasingly drive specialty drug spending and site-of-service decisions.
Key payers discussed include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. The publication outlines payer coverage patterns, common billing practices, typical sites of service, and coding-related considerations relevant to iloprost administration.
Readers will find benchmarks for unit-level reporting, a summary of payer considerations and prior-authorization trends, and the clinical context for iloprost use. The document also highlights implications for service line managers and revenue leaders, including how unit-based HCPCS reporting interacts with infusion workflows. Data not available in the input is noted where applicable, and the focus remains on national-level coding and billing context rather than state-specific policy.
Billing Code Overview
HCPCS Level II code J1749 represents the administration of iloprost by injection at a unit measure of 0.1 mcg. This code describes the drug product and is used to report the medication component of a patient encounter involving iloprost.
Service type: Therapeutic drug injection
Typical site of service: Hospital inpatient or outpatient infusion/administration areas, specialty clinics, or other clinical settings where parenteral medications are administered.
Clinical & Coding Specifications
Clinical Context
A patient with pulmonary arterial hypertension (PAH) or severe Raynaud phenomenon presents to an outpatient infusion center or hospital outpatient department for administration of inhaled or intravenous prostacyclin therapy. The billing code J1749 (Injection, iloprost, 0.1 mcg) is used when iloprost is prepared and dispensed for parenteral administration. Typical patients are adults with documented World Health Organization Group 1 pulmonary arterial hypertension who remain symptomatic despite oral therapy or who require prostacyclin analog therapy as part of combination treatment. The clinical workflow includes medication order verification by the prescribing pulmonologist or cardiologist, pharmacy compounding and verification, informed consent and allergy check, vascular access assessment (peripheral IV or central line if present), medication administration by an infusion nurse, monitoring for common adverse effects (hypotension, flushing, headache, jaw pain, nausea), and post‑administration vitals and documentation. The typical site of service is an outpatient infusion center, hospital outpatient department, or specialized pulmonary clinic; inpatient administration may occur for initiation or titration. Documentation should include indication, dose (number of 0.1 mcg units administered), route, lot number, date/time, administering clinician, and patient response or adverse events.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
00 |